Medicare GLP-1 Bridge — What the $50 Copay Pilot Actually Covers (2026)

For the first time since GLP-1 weight-loss medications hit the market, traditional Medicare will pay for them — at a $50 monthly copay, regardless of dose. The catch: the program runs for 18 months, covers a specific shortlist of drugs, and has clinical criteria most beneficiaries don't see in their pharmacy benefit letter.

CMS announced the demonstration on December 23, 2025 and updated the eligible-drug list on April 6 and May 12, 2026. We pulled the operational details from the CMS Bridge page itself — not the press summaries — so you can check eligibility honestly before walking into a prescriber's office.

What the Medicare GLP-1 Bridge actually is

The Bridge is a CMS short-term demonstration that runs July 1, 2026 → December 31, 2027. It operates outside the Part D benefit's regular payment flow — Humana acts as a single central processor for prior authorization, claims, and payment. Part D plans don't have to opt in, and the $50 copay you'll pay is the same regardless of dose escalation.

CMS describes it as a bridge to a longer-term program called BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), which itself is not yet launching. So 18 months of coverage is the actual horizon — assume nothing about what happens January 1, 2028.

Which drugs are covered

Only three brands, and only specific formulations:

• Foundayo® — all formulations (added April 6, 2026 after FDA approval)
• Wegovy® — all formulations (injection and tablets)
• Zepbound® KwikPen® only — the single-dose vial and single-dose pen formulations are not covered

Ozempic, Mounjaro, Saxenda, and Victoza are not in the program. CMS' rationale: only drugs used "to reduce excess body weight and maintain weight reduction" qualify — so the diabetes-indicated brands (Ozempic, Mounjaro) and the lower-effect labels are excluded.

Who qualifies — and at what BMI

You need to be on a standalone PDP or an MA-PD coordinated care plan. PACE participants and several other plan types are out unless they're also on a standalone PDP. Once enrollment is confirmed, a provider must attest that you met one of three clinical paths at the time you first initiated GLP-1 therapy — not today:

1. BMI ≥35 at therapy initiation, OR
2. BMI ≥30 with heart failure with preserved ejection fraction, OR uncontrolled hypertension (≥140/90 on two antihypertensives), OR chronic kidney disease stage 3a or above, OR
3. BMI ≥27 with pre-diabetes (ADA criteria), OR previous myocardial infarction, OR previous stroke, OR symptomatic peripheral artery disease.

The "time of initiation" clause matters. CMS gives a worked example: if you started a GLP-1 in September 2024 at BMI 37, and you're at BMI 34 by July 2026, the prescriber should attest to BMI ≥35 at initiation. The Bridge is designed to keep current users on therapy, not gate new starts harder than the existing FDA labels.

The numbers behind the $50

The manufacturers will net $245 per monthly supply under the program. Of that, $50 is your copay, and CMS' central processor reimburses pharmacies at the wholesale acquisition cost minus your copay, plus dispensing fees. That's roughly a 70% discount to current Medicare cash-pay reality (Wegovy lists around $1,349/month; Zepbound around $1,069/month).

The fine print that almost no summary covers:

• The $50 does not count toward your Part D deductible.
• The $50 does not count toward the $2,100 annual out-of-pocket cap.
• Manufacturer coupons and discount programs cannot be stacked.
• Low-Income Subsidy (Extra Help) does not apply to Bridge claims — even if you qualify for full LIS, you pay the full $50.
• Dually-eligible beneficiaries are eligible if their Part D plan type qualifies.

What this changes for you

If you're already on a covered GLP-1 and have been quietly paying $900–$1,300 a month, your prescriber should be putting Bridge prior-authorization paperwork in front of you the first week of July. If you're considering starting, the Bridge gives a predictable 18-month runway — but you still need to meet the clinical criteria as if you were starting today.

If you're on Mounjaro or Ozempic for weight loss specifically, the Bridge doesn't help you — yet. Watch for whether CMS expands the drug list later in 2026.

Use Gila's GLP-1 cost calculator with the $50 input to see your annualized spend versus your current path. If you're comparing branded vs. compounded — and the recent FDA 503B proposal puts compounded options under threat — the Bridge math may be the cheapest legal path forward for a Medicare beneficiary in 2026.

Key Takeaways

• The Medicare GLP-1 Bridge runs July 1, 2026 → December 31, 2027 at a flat $50 copay, no matter the dose.
• Covered: Wegovy (all), Foundayo (all), Zepbound KwikPen only. Ozempic and Mounjaro are NOT in the program.
• Eligibility is BMI-anchored: ≥35 alone, ≥30 with HFpEF / uncontrolled HTN / CKD 3a+, or ≥27 with prediabetes, prior MI, prior stroke, or PAD — measured at therapy initiation, not today.
• The $50 doesn't count toward Part D deductible or the $2,100 OOP cap; coupons cannot stack; LIS doesn't apply.
• Manufacturer net price: $245 per monthly supply. The math beats every branded cash-pay path except Lilly Direct vials for some Zepbound doses — and Zepbound vials are not in the Bridge.

Sources

• CMS Medicare GLP-1 Bridge FAQ (updated May 12, 2026)
• Medicare to launch weight loss drug option in July with $50 copay — NPR (May 6, 2026)
• KFF: What to Know About the BALANCE Model and Medicare GLP-1 Bridge

This article covers a Medicare policy change. It is not medical advice. Eligibility, formulary, and prior-authorization decisions belong to your prescriber and your Part D plan.